Literature DB >> 11497495

Effect of ulcerative colitis activity on plasma concentration of transforming growth factor beta1.

A Wiercińska-Drapało1, R Flisiak, D Prokopowicz.   

Abstract

Enhanced expression of transforming growth factor-beta1 (TGF-beta1) demonstrated in human colonic mucosa of patients with ulcerative colitis (UC), indicates its possible significance in the pathogenesis of this disease. The aim of this study was to evaluate plasma TGF-beta1 concentration in patients with different degrees of colonic mucosal injury, as a possible indicator of ulcerative colitis activity. TGF-beta1 concentration was measured with an enzyme immunoassay (EIA) in plasma of 45 patients with endoscopically confirmed UC. Values observed in UC patients (40.5+/-15.9 ng/ml) were significantly higher than in healthy people (18.3+/-11.6 ng/ml) and higher than in patients with irritable colon syndrome (ICS), (20.5+/-13.6 ng/ml). The highest plasma TGF-beta1 (58.6+/-112.1 ng/ml) was in patients with the severe UC course. TGF-beta1 level analysed in all UC patients revealed significant positive correlation with scored degree of mucosal injury (r=0.396;P<0.01). Among other possible laboratory markers of the disease activity, only C-reactive protein concentration demonstrated significant correlation. Enhanced production of TGF-beta1 can be related to inflammation activity. Measurement of plasma TGF-beta1 may be considered as a biomarker of the disease activity. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11497495     DOI: 10.1006/cyto.2001.0901

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  6 in total

1.  Exercise-induced changes in circulating levels of transforming growth factor-beta-1 in humans: methodological considerations.

Authors:  Katja Heinemeier; Henning Langberg; Michael Kjaer
Journal:  Eur J Appl Physiol       Date:  2003-07-09       Impact factor: 3.078

2.  Plasma interleukin-18 reflects severity of ulcerative colitis.

Authors:  Alicja Wiercinska-Drapalo; Robert Flisiak; Jerzy Jaroszewicz; Danuta Prokopowicz
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

3.  Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as biomarkers of ulcerative colitis activity.

Authors:  Alicja Wiercinska-Drapalo; Jerzy Jaroszewicz; Robert Flisiak; Danuta Prokopowicz
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

4.  Promoter polymorphism of transforming growth factor-beta1 gene and ulcerative colitis.

Authors:  B Tamizifar; K B Lankarani; S Naeimi; M Rismankar Zadeh; A Taghavi; A Ghaderi
Journal:  World J Gastroenterol       Date:  2008-01-14       Impact factor: 5.742

5.  The mRNA level of the transforming growth factor β1 gene, but not the amount of the gene product, can be considered as a potential prognostic parameter in inflammatory bowel diseases in children.

Authors:  Anna Liberek; Zbigniew Kmieć; Dorota Kartanowicz; Piotr M Wierzbicki; Marcin Stanisławowski; Lucyna Kaszubowska; Grażyna Luczak; Magdalena Góra-Gębka; Piotr Landowski; Agnieszka Szlagatys-Sidorkiewicz; Tomasz Liberek; Barbara Kamińska; Joanna Jakóbkiewicz-Banecka; Grzegorz Węgrzyn
Journal:  Int J Colorectal Dis       Date:  2012-05-15       Impact factor: 2.571

6.  Clinical Significance of Hepatocyte Growth Factor and Transforming Growth Factor-Beta-1 Levels in Assessing Disease Activity in Inflammatory Bowel Disease.

Authors:  Rania Naguib; Wafaa Mohamed El-Shikh
Journal:  Can J Gastroenterol Hepatol       Date:  2020-04-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.